Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Napabucasin suppressed tumor growth in DLBCL cell lines

Publish date:: September 2, 2020

Key clinical point: Napabucasin, a STAT3 inhibitor, suppressed tumor growth, exhibiting synergistic effects with doxorubicin in vitro and in vivo.

Major finding: A total of 34% (23/69) of DLBCL patients expressed STAT3 in tumor tissues.

Study details: Multiple DLBCL cell lines were tested in vivo as well as in vitro testing of biochemical effects.

Disclosures: The work was supported by grants from the Chinese government. The authors stated that they had no conflicts.

Citation:

Li X et al. Cancer Lett. 2020 Aug 14. doi: 10.1016/j.canlet.2020.07.032.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,